Jasper Therapeutics, Inc.
JSPRW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $187.1K in total; no superinvestor holds it.
Other share classesJSPR
Q1 2026 vs. Q4 2025
How the institutions holding Jasper Therapeutics, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 10 | 8 | −2 |
| Shares | 3.04M | 3.01M | −27.1K (−0.9%) |
| Value | $761.1K | $371.6K | −$389.5K (−51.2%) |
New holders (2)
Institutions that held Jasper Therapeutics, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 28,200 | $618 | 0.00% |
| Wolverine Asset Management LLC | 1,039 | $23 | 0.00% |
Sold out (4)
Institutions that held Jasper Therapeutics, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| T3 Companies, LLC | 14,200 | $569 |
| Bank of America Corp | 100 | $4 |
| Clear Street Group Inc. | 100 | $4 |
| Virtu Financial LLC | 10,114 | $0 |